Your browser is no longer supported. Please, upgrade your browser.
LGND Ligand Pharmaceuticals Incorporated daily Stock Chart
Ligand Pharmaceuticals Incorporated
Index- P/E13.70 EPS (ttm)8.82 Insider Own2.40% Shs Outstand21.63M Perf Week5.57%
Market Cap2.61B Forward P/E18.58 EPS next Y6.51 Insider Trans-27.32% Shs Float20.62M Perf Month9.82%
Income211.20M PEG0.55 EPS next Q1.06 Inst Own- Short Float38.35% Perf Quarter-18.57%
Sales242.30M P/S10.79 EPS this Y102.80% Inst Trans1.46% Short Ratio11.30 Perf Half Y-51.14%
Book/sh33.08 P/B3.65 EPS next Y10.74% ROA8.90% Target Price217.33 Perf Year-23.14%
Cash/sh51.41 P/C2.35 EPS next 5Y25.00% ROE21.60% 52W Range98.56 - 278.62 Perf YTD-10.94%
Dividend- P/FCF13.69 EPS past 5Y74.60% ROI8.70% 52W High-56.62% Beta1.38
Dividend %- Quick Ratio2.20 Sales past 5Y35.10% Gross Margin97.90% 52W Low22.63% ATR5.52
Employees39 Current Ratio2.20 Sales Q/Q36.80% Oper. Margin62.80% RSI (14)50.20 Volatility3.20% 4.07%
OptionableYes Debt/Eq1.17 EPS Q/Q682.80% Profit Margin49.50% Rel Volume0.66 Prev Close120.88
ShortableYes LT Debt/Eq0.86 EarningsFeb 07 AMC Payout0.00% Avg Volume699.75K Price120.86
Recom1.90 SMA203.61% SMA50-6.80% SMA200-36.11% Volume463,355 Change-0.02%
Oct-29-18Upgrade ROTH Capital Neutral → Buy
Oct-02-18Reiterated H.C. Wainwright Buy $270 → $280
Sep-11-18Reiterated Argus Buy $260 → $300
Aug-17-18Initiated Goldman Neutral $256
Aug-08-18Downgrade ROTH Capital Buy → Neutral
Jun-21-18Initiated Argus Buy $260
Dec-27-17Reiterated H.C. Wainwright Buy $163 → $169
Sep-05-17Resumed H.C. Wainwright Buy $150
Oct-05-16Reiterated H.C. Wainwright Buy $146 → $160
Aug-05-16Downgrade Deutsche Bank Hold → Sell $104 → $110
Mar-11-16Initiated Sidoti Buy
Mar-03-16Initiated H.C. Wainwright Buy $146
Dec-18-15Reiterated ROTH Capital Buy $144 → $146
Nov-19-15Reiterated ROTH Capital Buy $138 → $144
Sep-30-15Reiterated ROTH Capital Buy $135 → $140
Jun-19-15Reiterated Cantor Fitzgerald Hold $86 → $93
Jun-15-15Downgrade Deutsche Bank Buy → Hold $94
Jun-05-15Reiterated ROTH Capital Buy $127 → $135
Apr-01-15Reiterated Deutsche Bank Buy $74 → $94
Mar-03-15Initiated CRT Capital Buy $102
Feb-13-19 03:34PM  Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars Zacks
Feb-11-19 05:15PM  Edited Transcript of LGND earnings conference call or presentation 7-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
09:39AM  Merrimack (MACK) Stock Up Year to Date: Is a Rebound Likely? Zacks
Feb-08-19 10:00AM  AMAG Q4 Loss Narrower Than Expected, Revenues Lag Estimates Zacks
08:03AM  Ligand (LGND) Beats on Q4 Earnings & Sales, Raises '19 View Zacks
Feb-07-19 09:57PM  Ligand Pharmaceuticals Inc (LGND) Q4 2018 Earnings Conference Call Transcript Motley Fool
05:20PM  Ligand Pharmaceuticals (LGND) Q4 Earnings and Revenues Top Estimates Zacks
04:21PM  Ligand: 4Q Earnings Snapshot Associated Press
04:01PM  Ligand Reports Fourth Quarter and Full Year 2018 Financial Results Business Wire
09:00AM  Ligand Announces OmniAb® Partnership with Genagon Therapeutics Business Wire
Feb-06-19 10:31AM  Vertex (VRTX) Q4 Earnings Beat on Solid CF Products Sales Zacks
Feb-04-19 04:01PM  Ligand Announces Investment in Dianomi Therapeutics Business Wire
Feb-01-19 07:40AM  Consolidated Research: 2019 Summary Expectations for Micron Technology, Quidel, Ligand Pharmaceuticals, Altra Industrial Motion, USG, and Equity Lifestyle Properties Fundamental Analysis, Key Performance Indications GlobeNewswire
Jan-29-19 12:34PM  Bragar Eagel & Squire, P.C. is Investigating Ligand Pharmaceuticals Incorporated (LGND) on Behalf of Stockholders and Encourages LGND Investors to Contact the Firm GlobeNewswire
Jan-25-19 09:00AM  Ligand Partner Seelos Therapeutics Becomes a Public Company Business Wire
Jan-24-19 08:01AM  Seelos Therapeutics, Inc. Announces Successful Completion of its Merger with Apricus Biosciences, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System (CNS) Disorders GlobeNewswire
Jan-18-19 10:42AM  Who Has Been Selling Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares? Simply Wall St. +6.48%
Jan-17-19 08:00PM  INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Ligand Pharmaceuticals Incorporated Business Wire
01:40PM  Viking Therapeutics Stock Regains Ground Investopedia
12:45PM  Bragar Eagel & Squire, P.C. is Investigating Ligand Pharmaceuticals Incorporated (LGND) on Behalf of Stockholders and Encourages LGND Investors to Contact the Firm GlobeNewswire
11:31AM  Ligand (LGND) Takes a Hit on Citron's Negative Research Report Zacks
10:00AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Ligand Pharmaceuticals Incorporated (LGND) GlobeNewswire
08:06AM  The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US Benzinga
08:00AM  Today's Research Reports on Trending Tickers: Ligand Pharmaceuticals and FibroGen ACCESSWIRE
06:59AM  Rev. Fr. Emmanuel Lemelson Renews Call for Investigation in Alleged Accounting and Securities Fraud, SEC Failures, at Ligand Pharmaceuticals PR Newswire
06:55AM  Citron Says Ligand Has 80% Downside in Explosive Note Investopedia
Jan-16-19 08:29PM  Here's Why Ligand Pharmaceuticals Plummeted 16% Today Motley Fool -16.48%
06:38PM  Wolf Popper LLP Announces Investigation on Behalf of Investors in Ligand Pharmaceuticals Incorporated PR Newswire
04:22PM  Ligand Pharmaceuticals Tumbles After Short-Seller Andrew Left Slams the Stock
04:18PM  Ligand Crashes To Nearly 2-Year Low After Short-Seller Bashes It Investor's Business Daily
03:35PM  Ligand Pharmaceuticals Hit By Bearish Citron Report Benzinga
02:08PM  Former California Deputy Attorney General and Special Prosecutor with Johnson Fistel Launches Investigation into Ligand Pharmaceuticals; Investors Suffering Losses Encouraged to Contact Firm PR Newswire
01:19PM  Ligand Pharma stock tanks after short seller Citron calls it 'pipe dream' MarketWatch
Jan-15-19 02:00PM  Ligand to Report Fourth Quarter and Full Year 2018 Results on February 7th Business Wire
Dec-18-18 05:00PM  Ligand Introduces 2019 Financial Outlook and Raises 2018 Financial Guidance Business Wire
11:53AM  Rare disease treatment developer Palvella signs $10M funding deal American City Business Journals
08:00AM  The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan Benzinga
Dec-17-18 04:01PM  Ligand Acquires Milestone and Royalty Rights to PTX-022 from Palvella Therapeutics Business Wire
09:00AM  Vernalis Research, a Ligand Company, Achieves Success Milestone in Collaboration with Asahi Kasei Pharma Business Wire
Dec-12-18 03:28AM  Ligand Pharmaceuticals Inc. (LGND) Hedge Funds Are Snapping Up Insider Monkey
Dec-10-18 10:00AM  Sermonix Announces FDA Acceptance of IND Application; Will Begin Phase 2 Trial of Lasofoxifene for Targeted Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer GlobeNewswire
Dec-08-18 09:30AM  Why Is Ligand (LGND) Down 14.9% Since Last Earnings Report? Zacks
Nov-29-18 08:50AM  Detailed Research: Economic Perspectives on American Tower Corporation (REIT), Ligand Pharmaceuticals, Teva Pharmaceutical Industries, Cummins, Alexander's, and Korea Electric Power What Drives Growth in Today's Competitive Landscape GlobeNewswire
Nov-28-18 02:35PM  Why Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Looks Like A Quality Company Simply Wall St.
Nov-21-18 11:11AM  10 Triple-A Stocks to Buy for the Rest of 2018 InvestorPlace
09:00AM  Ligand Announces OmniAb® Partnership with iMetabolic Biopharma Corporation Business Wire
Nov-15-18 05:27AM  Edited Transcript of LGND earnings conference call or presentation 8-Nov-18 2:00pm GMT Thomson Reuters StreetEvents
Nov-14-18 10:00AM  Sermonix Pharmaceuticals to Present Three Posters Focused on Precision Medicine in the Treatment of Metastatic Breast Cancer at San Antonio Breast Cancer Symposium GlobeNewswire
Nov-13-18 09:00AM  Vernalis Research, a Ligand Company, Achieves Success Milestones in Collaboration with Daiichi Sankyo Business Wire
Nov-09-18 07:41AM  Ligand (LGND) Beats on Q3 Earnings & Revenues, Raises View Zacks -7.36%
07:00AM  Today's Research Reports on Trending Tickers: Ligand Pharmaceuticals and Intrexon ACCESSWIRE
Nov-08-18 12:36PM  Ligand Pharmaceuticals Inc (LGND) Q3 2018 Earnings Conference Call Transcript Motley Fool +5.04%
09:30AM  Ligand Pharmaceuticals (LGND) Tops Q3 Earnings and Revenue Estimates Zacks
08:26AM  Ligand: 3Q Earnings Snapshot Associated Press
08:00AM  Ligand Reports Third Quarter 2018 Financial Results Business Wire
Nov-06-18 11:13AM  What Lies in Store for Ligand (LGND) This Earnings Season? Zacks
Nov-02-18 09:00AM  Ligand to Participate in Stephens NY Investment Conference Business Wire
Nov-01-18 08:54AM  3 Hammered Healthcare Stocks to Buy Now Motley Fool
Oct-30-18 06:09PM  Keysight Technologies Set to Join S&P 500; Ligand Pharmaceuticals to Join S&P MidCap 400; Marcus & Millichap and Arcosa to Join S&P SmallCap 600 PR Newswire
05:01PM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Oct-25-18 05:45PM  Ligand Pharmaceuticals (LGND) Gains But Lags Market: What You Should Know Zacks
Oct-22-18 09:15AM  Analysis: Positioning to Benefit within Ligand Pharmaceuticals, AptarGroup, Unifirst, Universal, AutoZone, and Churchill Downs Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Oct-17-18 02:27PM  5 Beaten-Down Biotech Stocks to Pick Up from the Wreckage InvestorPlace
Oct-15-18 09:00AM  Ligand to Report Third Quarter 2018 Results on November 8th Business Wire
Oct-12-18 05:45PM  Ligand Pharmaceuticals (LGND) Stock Sinks As Market Gains: What You Should Know Zacks
Oct-10-18 02:25PM  Utilities, Defensive Stocks Buck Drop; Is It Time To Sell Microsoft Stock? Investor's Business Daily -9.01%
09:00AM  Ligand Announces the Close of its Acquisition of Vernalis Business Wire
Oct-09-18 12:00PM  Orchestra BioMed Adds Three Industry Leaders to Strategic Advisory Board GlobeNewswire
10:00AM  Sermonix Launches Phase 2 Trial to Evaluate Investigational Oral Lasofoxifene as a Targeted Precision Treatment for Women With ESR1 Mutations in Metastatic Breast Cancer GlobeNewswire
Oct-08-18 09:23AM  bluebird's MAA for LentiGlobin Gene Therapy Accepted by EMA Zacks
Oct-06-18 08:00AM  3 Top Mid-Cap Stocks to Buy Right Now Motley Fool
Oct-05-18 10:01AM highlights: MCBC Holdings, Newpark Resources, Cigna, Weight Watchers International and Ligand Pharmaceuticals Zacks
Oct-04-18 03:18PM  Alnylam Files Clinical Trial Application for ALN-AAT02 in UK Zacks
09:45AM  VistaGen Up on Fast Track Designation to Pain Candidate Zacks
09:18AM  5 Stocks With High Net Income Ratio to Scoop Up Zacks
Oct-03-18 12:01PM  Stock Market Sails Ahead On 3 Economic Reports Investor's Business Daily
10:37AM  Paratek (PRTK) Gets FDA Approval for Nuzyra and Seysara Zacks
Sep-28-18 10:58AM  Ultragenyx Reports Top-line Data From Gene Therapy Candidate Zacks
10:06AM  3 Biotech Stocks With Rising Estimates in the Past Month Zacks
07:37AM  Best ETFs for 2018: Dont Sweat This Quarter for the SBIO ETF InvestorPlace
Sep-27-18 05:46PM  Amarin's Stock Soars as Fish Oil Drug Lowers Heart Risks Zacks
04:13PM  Techs Lift Stock Market, But This Other Sector Stands Out Investor's Business Daily
08:48AM  Time to Focus on Ligand Pharmaceuticals (LGND) for Strong Earnings Growth Potential Zacks
Sep-26-18 02:25PM  These Medical Stocks Lead Market Higher After Fed Rate Hike; Will Netflix Break Out? Investor's Business Daily
Sep-25-18 06:05PM  Alexion's Soliris Successful in Phase III Study for NMOSD Zacks
10:52AM  FDA Lifts Clinical Hold on Epizyme's Lead Candidate's Study Zacks
10:44AM  FDA Lifts Clinical Hold on Sarepta's DMD Gene Therapy Program Zacks
Sep-24-18 04:49PM  Exelixis, Ipsen Receive Positive CHMP Opinion for Cabometyx Zacks
04:43PM  CHMP Reconfirms Negative Opinion for Sarepta's Exondys Zacks
Sep-21-18 06:12PM  FDA Confirms Positive Safety Profile of Acadia's Nuplazid Zacks
03:39PM  Does Ligand Pharmaceuticals Incorporateds (NASDAQ:LGND) Debt Level Pose A Problem? Simply Wall St.
09:30AM  Is Ligand Pharmaceuticals (LGND) Stock Outpacing Its Medical Peers This Year? Zacks
Sep-20-18 03:49PM  Ultragenyx's Shares Surge More Than 80% in the Year So Far Zacks
03:12PM  The 7 Best Biotech Stocks for Investors Who Hate Risk Kiplinger
10:43AM  Progenics Pharma's Stock Down on Dismal Phase III Study Data Zacks
Sep-19-18 06:54AM highlights: Attunity, Helix Energy Solutions Group, Ligand Pharmaceuticals, Turtle Beach and SVB Financial Group Zacks
Sep-18-18 10:20AM  Stocks Rally Amid U.S-China Tariff Exchange; FedEx Skids On EPS Investor's Business Daily
09:03AM  Enhance Your Gains With These 5 Best Profitable Stocks Zacks
08:50AM  Cytori's Chemotherapy Candidate Gets Orphan Drug Status Zacks
Sep-13-18 11:42AM  The Crisis Was in the System Bloomberg
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular diseases, muscle wasting, liver and kidney diseases, and others. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Berkman Charles SSVP, Gen. Counsel & SecretaryJan 10Option Exercise65.622,850187,02939,913Jan 14 09:17 AM
HIGGINS JOHN LChief Executive OfficerJan 10Option Exercise16.1433,790545,371119,209Jan 14 09:16 AM
Berkman Charles SSVP, Gen. Counsel & SecretaryDec 17Option Exercise21.923,40074,52837,063Dec 17 07:58 PM
FOEHR MATTHEW WPresident and COODec 12Option Exercise9.977,99979,750113,387Dec 12 05:32 PM
Berkman Charles SSVP, Gen. Counsel & SecretaryOct 24Option Exercise16.793,90065,46233,663Oct 25 05:44 PM
Davis Todd CDirectorOct 12Option Exercise103.295,083525,02147,639Oct 15 12:55 PM
Berkman Charles SSVP, Gen. Counsel & SecretaryOct 11Option Exercise14.472,00028,94029,763Oct 12 06:52 PM
Davis Todd CDirectorOct 08Sale253.992,500634,97842,556Oct 09 04:24 PM
FOEHR MATTHEW WPresident and COOOct 01Option Exercise13.8014,088194,457117,388Oct 02 06:24 PM
KOZARICH JOHN WDirectorOct 01Sale275.042,500687,61026,142Oct 02 06:24 PM
FOEHR MATTHEW WPresident and COOOct 01Sale273.8812,0003,286,560105,388Oct 02 06:24 PM
Berkman Charles SSVP, Gen. Counsel & SecretarySep 17Option Exercise100.382,813282,36930,576Sep 18 06:16 PM
Berkman Charles SSVP, Gen. Counsel & SecretarySep 17Sale250.692,813705,18127,763Sep 18 06:16 PM
Berkman Charles SSVP, Gen. Counsel & SecretarySep 04Option Exercise69.9819,4171,358,79647,180Sep 05 08:00 PM
FOEHR MATTHEW WPresident and COOSep 04Option Exercise14.1113,044184,049115,300Sep 05 08:18 PM
LAMATTINA JOHN LDirectorSep 04Option Exercise12.533,33541,78824,784Sep 05 07:59 PM
Sabba Stephen LDirectorSep 04Option Exercise13.235,00066,15031,856Sep 06 10:40 AM
LAMATTINA JOHN LDirectorSep 04Sale254.963,335850,29221,449Sep 05 07:59 PM
FOEHR MATTHEW WPresident and COOSep 04Sale255.0112,0003,060,082103,300Sep 05 08:18 PM
Sabba Stephen LDirectorSep 04Sale255.055,0001,275,25026,856Sep 06 10:40 AM
Berkman Charles SSVP, Gen. Counsel & SecretarySep 04Sale254.9919,4174,951,06527,763Sep 05 08:00 PM
HIGGINS JOHN LChief Executive OfficerAug 30Sale258.253,500903,87585,419Aug 31 01:22 PM
Korenberg Matthew EEVP,Finance & Strategy and CFOAug 29Option Exercise85.7911,540990,01725,099Aug 29 08:35 PM
Korenberg Matthew EEVP,Finance & Strategy and CFOAug 29Sale256.6918,3574,712,0606,742Aug 29 08:35 PM
HIGGINS JOHN LChief Executive OfficerAug 17Option Exercise14.4712,993188,009101,912Aug 17 07:37 PM
Aryeh JasonDirectorAug 17Sale241.8126,8626,495,55951,392Aug 17 07:38 PM
HIGGINS JOHN LChief Executive OfficerAug 17Sale243.0012,9933,157,29988,919Aug 17 07:37 PM
Davis Todd CDirectorAug 17Sale239.503,167758,49745,056Aug 17 07:38 PM
Patel SunilDirectorAug 16Option Exercise16.7027,005451,05866,811Aug 17 07:37 PM
HIGGINS JOHN LChief Executive OfficerAug 16Option Exercise14.473,00743,511110,426Aug 17 07:37 PM
HIGGINS JOHN LChief Executive OfficerAug 16Sale241.3321,5075,190,26188,919Aug 17 07:37 PM
Davis Todd CDirectorAug 16Sale239.935,8331,399,50548,223Aug 17 07:38 PM
Patel SunilDirectorAug 16Sale240.0542,28710,150,80824,524Aug 17 07:37 PM
Aryeh JasonDirectorAug 16Sale245.001,080264,60078,254Aug 17 07:38 PM
KOZARICH JOHN WDirectorJul 02Sale207.482,500518,69928,642Jul 03 06:50 PM
LAMATTINA JOHN LDirectorJun 04Option Exercise12.534,00050,12024,956Jun 04 07:01 PM
LAMATTINA JOHN LDirectorJun 04Sale194.514,000778,03920,956Jun 04 07:01 PM
HIGGINS JOHN LChief Executive OfficerMay 15Option Exercise16.1412,405200,217119,824May 15 06:41 PM
HIGGINS JOHN LChief Executive OfficerMay 15Sale179.9712,4052,232,491107,419May 15 06:41 PM
FOEHR MATTHEW WPresident and COOMay 10Option Exercise13.999,936139,026110,082May 11 05:32 PM
FOEHR MATTHEW WPresident and COOMay 10Sale167.638,8811,488,687101,201May 11 05:32 PM
KOZARICH JOHN WDirectorApr 02Sale160.432,500401,06330,649Apr 03 04:50 PM
Sabba Stephen LDirectorMar 12Sale180.73622112,41426,363Mar 13 06:15 PM
Aryeh JasonDirectorMar 09Sale176.474,000705,89979,334Mar 09 06:28 PM
Aryeh JasonDirectorMar 08Sale174.883,500612,09583,334Mar 09 06:28 PM
LAMATTINA JOHN LDirectorMar 05Option Exercise10.123,33533,75024,291Mar 06 06:36 PM
LAMATTINA JOHN LDirectorMar 05Sale160.903,335536,60420,956Mar 06 06:36 PM
Davis Todd CDirectorFeb 27Sale151.9012,3351,873,70953,563Feb 27 06:39 PM
Davis Todd CDirectorFeb 26Sale153.584,835742,53665,898Feb 27 06:39 PM
FOEHR MATTHEW WPresident and COOFeb 23Option Exercise13.776,44888,785101,279Feb 27 06:39 PM
Aryeh JasonDirectorFeb 23Sale155.003,417529,63586,834Feb 27 06:40 PM
FOEHR MATTHEW WPresident and COOFeb 23Sale152.985,444832,82495,835Feb 27 06:39 PM